Thermo Fisher Scientific said revenue for Q2 2025 ended June 28, 2025 grew 3% to $10.85 billion from $10.54 billion in the year-ago period, and GAAP diluted EPS grew to $4.28 from $4.04.

1. 01

   Thermo Fisher Scientific said revenue for Q2 2025 ended June 28, 2025 grew 3% to $10.85 billion from $10.54 billion in the year-ago period, and GAAP diluted EPS grew to $4.28 from $4.04.

2. 02

   The company said adjusted EPS for Q2 was $5.36, compared with $5.37 in the year-ago quarter, adjusted operating margin was 21.9%, compared with 22.3% in the year-ago quarter, and GAAP operating margin was 16.9%, compared with 17.3% in the year-ago quarter.

3. 03

   Thermo Fisher Scientific disclosed that net cash provided by operating activities for the 6 months ended 2025 was $2,122 million, compared with $3,211 million in the year-ago period, and free cash flow (non-GAAP) was $1,479 million, compared with $2,583 million in the year-ago period.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.